Last Modified: March 10, 2025
Est. Read Time: 2 min read
Fact Checked
Expert Verified

Our content is developed and backed by respected legal, medical and scientific experts. More than 30 contributors, including product liability attorneys and board-certified physicians, have reviewed our website to ensure it’s medically sound and legally accurate.

Why Trust Drugwatch?
Drugwatch is trusted
legal help when you need it most.

Drugwatch has provided people injured by harmful drugs and devices with reliable answers and experienced legal help since 2009. Brought to you by Wilson & Peterson LLP, we've pursued justice for more than 20,000 families and secured $324 million in settlements and verdicts against negligent manufacturers.

More than 30 contributors, including mass tort attorneys and board-certified doctors, have reviewed our website and added their unique perspectives to ensure you get the most updated and highest quality information.

Drugwatch.com is AACI-certified as a trusted medical content website and is produced by lawyers, a patient advocate and award-winning journalists whose affiliations include the American Bar Association and the American Medical Writers Association.

About Drugwatch.com

  • 15+ Years of Advocacy
  • $324 Million Recovered for Clients
  • 20,000 Families Helped
  • A+ BBB Rating
  • 4.9 Stars from Google Reviews
Learn More About Us

Testimonials

I found Drugwatch to be very helpful with finding the right lawyers. We had the opportunity to share our story as well, so that more people can be aware of NEC. We are forever grateful for them.
Chasity P. Legal Client
  • Google Business Rating
  • BBB A+ Rating Logo

A lawsuit filed in California accused the makers of a popular breast cancer chemotherapy drug of hiding side effects, including permanent hair loss, and misrepresenting the drug’s benefits.

Ami Dodson filed a lawsuit against Sanofi-Aventis, the makers of the chemotherapy drug, Taxotere (docetaxel), claiming the drug caused her to suffer permanent hair loss (alopecia). Furthermore, she said the drug maker engaged in marketing schemes to drive up the sales of the drug while hiding the medication’s increased toxicity compared to other similar drugs.

Nearly 3 million women have a history of breast cancer in the U.S. Of these women, about 75 percent were prescribed Taxotere.

“Defendants [preyed] on one of the most vulnerable group of individuals at the most difficult time in their lives,” Dodson said in her complaint. “Defendants obtained billions of dollars in increased revenues at the expense of unwary cancer victims simply hoping to survive their condition and return to a normal life.”

The U.S. Food and Drug Administration (FDA) first approved Taxotere in 1996 and by 2004, it raked in $1.4 billion each year for Sanofi. The drug is approved for use in treating a variety of cancers. In 2004, the FDA approved the drug despite significant toxicity that could cause leukemia and congestive heart failure, according to the National Cancer Institute.

Dodson claims she would not have used Taxotere if she had known it could cause permanent hair loss, especially since other less toxic options were available.

“Permanent baldness (permanent alopecia) is a disfiguring condition, especially for women,” said Dodson. “Women who experienced disfiguring permanent alopecia as a result of the use of Taxotere suffer great mental anguish as well as economic damages, including but not limited to loss of work or inability to work due to significant psychological damage.”

Legal experts claim many more Taxotere lawsuits like Dodson’s will be filed.

Side Effect Information
Studies have linked Taxotere to permanent and irreversible eye damage. Learn more about the serious side effects associated with taking Taxotere.

Sanofi ‘Concealed’ Studies Showing Taxotere Side Effects

Although temporary hair loss occurs after treatment with chemotherapy drugs, in most cases the hair grows back. Permanent alopecia is uncommon. The issue with Taxotere is that studies show it has an increased risk that hair will not grow back after use. Hair loss can occur over the entire body, including loss of eyebrows, eyelashes and pubic hair.

When combined with other chemo drugs, the hair loss can be more devastating, according to the Rocky Mountain Cancer Center in Colorado. According to the center, it saw permanent hair loss in up to 6.3 percent of its patients.

In the 1990s, Sanofi and Aventis sponsored the GEICAM study. By 2005, results of the study showed 9.2 percent of patients suffered from hair loss that lasted 10 years or longer. The Dodson lawsuit alleges the drug makers withheld these results from the public.

Sanofi warned a few other countries about alopecia risk but did not warn women in the U.S. Instead, Dodson says the company gave a vague warning that said “hair generally grows back” after its loss.

Sanofi has yet to issue a statement in response to the allegations.

Disclaimer: Thoughts and opinions expressed in this patient story are strictly anecdotal and should not be taken as medical information or advice. Views of the interviewee do not necessarily reflect those of the author, editor or Drugwatch.